trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Carcinoma D002277 18 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Brain Neoplasms D001932 15 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Melanoma D008545 69 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Asthma D001249 52 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Intellectual Disability D008607 13 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Endometriosis D004715 29 associated lipids
Uterine Neoplasms D014594 18 associated lipids
Adrenoleukodystrophy D000326 29 associated lipids
Prostatic Hyperplasia D011470 20 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Myeloproliferative Disorders D009196 5 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Fibrosis D005355 23 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Carcinoma, Renal Cell D002292 12 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Leukemia, Promyelocytic, Acute D015473 3 associated lipids
Stroke D020521 32 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Nerve Degeneration D009410 53 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Hypertension D006973 115 associated lipids
Tongue Neoplasms D014062 15 associated lipids
Cytomegalovirus Infections D003586 7 associated lipids
Nasal Polyps D009298 26 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Mast-Cell Sarcoma D012515 9 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Neoplasms, Hormone-Dependent D009376 23 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Translocation, Genetic D014178 20 associated lipids
Cardiomegaly D006332 31 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Radiation Injuries D011832 14 associated lipids
Leishmaniasis D007896 19 associated lipids
Enteritis D004751 8 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Chondrosarcoma D002813 9 associated lipids
Osteomalacia D010018 5 associated lipids
Glioblastoma D005909 27 associated lipids
Keloid D007627 12 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Medulloblastoma D008527 22 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Lymphatic Metastasis D008207 10 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Bone Marrow Neoplasms D019046 2 associated lipids
Carcinoma, Pancreatic Ductal D021441 6 associated lipids
Cat Diseases D002371 12 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Polycystic Kidney, Autosomal Dominant D016891 6 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Retinoblastoma D012175 12 associated lipids
Genomic Instability D042822 7 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Carcinoma, Embryonal D018236 8 associated lipids
Mastocytoma D034801 3 associated lipids
Cell Transformation, Viral D002472 26 associated lipids
Nasopharyngeal Neoplasms D009303 4 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Adenocarcinoma, Follicular D018263 3 associated lipids
Hypereosinophilic Syndrome D017681 3 associated lipids
Retinal Neoplasms D019572 3 associated lipids
Progeria D011371 3 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Lee SK et al. Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-kappaB, and serum response factor. 2000 J. Biol. Chem. pmid:10777532
Zhang HS et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. 2000 Cell pmid:10778858
Fu M et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. 2000 J. Biol. Chem. pmid:10779504
Gays F et al. The mouse tumor cell lines EL4 and RMA display mosaic expression of NK-related and certain other surface molecules and appear to have a common origin. 2000 J. Immunol. pmid:10799866
McInerney JM et al. Long-term silencing of retroviral vectors is resistant to reversal by trichostatin A and 5-azacytidine. 2000 Gene Ther. pmid:10800088
McBlane F and Boyes J Stimulation of V(D)J recombination by histone acetylation. 2000 Curr. Biol. pmid:10801420
Hobbs CA and Gilmour SK High levels of intracellular polyamines promote histone acetyltransferase activity resulting in chromatin hyperacetylation. 2000 J. Cell. Biochem. pmid:10760944
Yoshida M and Horinouchi S [Histone deacetylase inhibitors--new anticancer agents?]. 2000 Tanpakushitsu Kakusan Koso pmid:10771678
Xu RH et al. Histone acetylation is a checkpoint in FGF-stimulated mesoderm induction. 2000 Dev. Dyn. pmid:10906781
Gray SG et al. IGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with trichostatin a. 2000 Cytokine pmid:10880258
Su GH et al. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. 2000 Cancer Res. pmid:10866300
Lin F et al. Unique anti-activator protein-1 activity of retinoic acid receptor beta. 2000 Cancer Res. pmid:10866321
Hemavathy K et al. Human Slug is a repressor that localizes to sites of active transcription. 2000 Mol. Cell. Biol. pmid:10866665
Jin S et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. 2000 Proc. Natl. Acad. Sci. U.S.A. pmid:10841572
Claassen GF and Hann SR A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. 2000 Proc. Natl. Acad. Sci. U.S.A. pmid:10920185
Mao C and Shapiro DJ A histone deacetylase inhibitor potentiates estrogen receptor activation of a stably integrated vitellogenin promoter in HepG2 cells. 2000 Endocrinology pmid:10875235
DiRenzo J et al. BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. 2000 Mol. Cell. Biol. pmid:11003650
Hu JF et al. Allele-specific histone acetylation accompanies genomic imprinting of the insulin-like growth factor II receptor gene. 2000 Endocrinology pmid:11108251
Tobias CA et al. Improved recombinant retroviral titers utilizing trichostatin A. 2000 BioTechniques pmid:11056820
Dressel U et al. Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer. 2000 Mar-Apr Anticancer Res. pmid:10810390
Steinbac OC et al. Histone deacetylase activity is required for the induction of the MyoD muscle cell lineage in Xenopus. 2000 Sep-Oct Biol. Chem. pmid:11076034
Plant KE et al. Intergenic transcription in the human beta-globin gene cluster. 2001 Mol. Cell. Biol. pmid:11533239
Chen Lf W et al. Duration of nuclear NF-kappaB action regulated by reversible acetylation. 2001 Science pmid:11533489
Vinatzer U et al. The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. 2001 Br. J. Haematol. pmid:11552981
Sekimata M et al. Involvement of a novel zinc finger protein, MIZF, in transcriptional repression by interacting with a methyl-CpG-binding protein, MBD2. 2001 J. Biol. Chem. pmid:11553631
Deltour S et al. Characterization of HRG22, a human homologue of the putative tumor suppressor gene HIC1. 2001 Biochem. Biophys. Res. Commun. pmid:11554746
Kiela PR et al. Regulation of the rat NHE3 gene promoter by sodium butyrate. 2001 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:11557515
Bovenzi V and Momparler RL Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. 2001 Cancer Chemother. Pharmacol. pmid:11488527
Franco PJ et al. The orphan nuclear receptor TR2 interacts directly with both class I and class II histone deacetylases. 2001 Mol. Endocrinol. pmid:11463856
Pujuguet P et al. Trichostatin A inhibits beta-casein expression in mammary epithelial cells. 2001 J. Cell. Biochem. pmid:11746508
Benjamin D and Jost JP Reversal of methylation-mediated repression with short-chain fatty acids: evidence for an additional mechanism to histone deacetylation. 2001 Nucleic Acids Res. pmid:11522830
Vigushin DM et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. 2001 Clin. Cancer Res. pmid:11309348
Magdinier F and Wolffe AP Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11309512
Grande A et al. A functionally active RARalpha nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines. 2001 Cell Death Differ. pmid:11313705
Wu Y et al. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. 2001 Oncogene pmid:11313951
Greenberg VL et al. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. 2001 Thyroid pmid:11349829
Lea MA et al. Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. 2001 Int. J. Cancer pmid:11351296
Jordan A et al. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. 2001 EMBO J. pmid:11285236
Rashid SF et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. 2001 Oncogene pmid:11313934
Bachl J et al. Increased transcription levels induce higher mutation rates in a hypermutating cell line. 2001 J. Immunol. pmid:11290786
Mishra N et al. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11226290
Feng YQ et al. Position effects are influenced by the orientation of a transgene with respect to flanking chromatin. 2001 Mol. Cell. Biol. pmid:11113204
Osborne A et al. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. 2001 Mol. Cell. Biol. pmid:11533238
Nervi C et al. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. 2001 Cancer Res. pmid:11245412
Zhu WG et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. 2001 Cancer Res. pmid:11245429
Muth V et al. Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription. 2001 EMBO J. pmid:11250901
Laribee RN and Klemsz MJ Loss of PU.1 expression following inhibition of histone deacetylases. 2001 J. Immunol. pmid:11673528
Biade S et al. Chemical agents that promote chromatin compaction radiosensitize tumour cells. 2001 Int. J. Radiat. Biol. pmid:11682008
Mishra SK et al. Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells. 2001 FEBS Lett. pmid:11682064
Sharma M and Sun Z 5'TG3' interacting factor interacts with Sin3A and represses AR-mediated transcription. 2001 Mol. Endocrinol. pmid:11682623